Stocks
Spero Secures Cash Runway to H2 2029 with $105M Financing
Spero Therapeutics has extended its cash runway into the second half of 2029 following a $105 million nondilutive royalty financing. This move,...
#pharmaceuticals 29 articles
Stocks
Atea Projects Over $700M Annual U.S. HCV Revenue Potential
Atea Pharmaceuticals (AVIR) outlined peak annual U.S. net revenue potential exceeding $700 million, driven by its mid-2028 hepatitis C (HCV) launch. This...
Stocks
Goldman-Backed Attovia Raises $289 Million in Top-Priced US IPO
Attovia Therapeutics, an early-stage biotech firm backed by Goldman Sachs, successfully raised $289 million in its US IPO, pricing at the top...
Stocks
Summit Therapeutics Sets November 14 FDA PDUFA Date for Ivonescimab
Summit Therapeutics has received a November 14 PDUFA date for its ivonescimab BLA. The company is also planning the HARMONi-3 PFS trial...
Economy
Trump Imposes 100% Tariff on Generic Drugs, Sets 2028 US Production Deadline
President Donald Trump announced a 100% import duty on generic drugs from August 2028, giving manufacturers two years to move production to...
Stocks
FDA Clears Subcutaneous Leqembi Iqlik for At-Home Use
The FDA has approved Biogen and Eisai's Leqembi Iqlik, a subcutaneous version of their Alzheimer's treatment, for initiation and maintenance dosing, including...
Stocks
HHS, VA Memorandum Boosts Psychedelic Drugmakers
A new memorandum of understanding between HHS and the VA could significantly benefit companies developing psychedelic-based drug treatments for veterans.
Stocks
AbbVie’s Skyrizi Expands Pediatric Indication to Psoriatic Diseases
AbbVie's Skyrizi has received US FDA approval for children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This...
Stocks
Definium Therapeutics Prices $700M Public Offering
Definium Therapeutics announced the pricing of an upsized public offering, raising approximately $700 million in gross proceeds.